Iqvia Holdings Inc (IQV) Receives $131.06 Average Target Price from Brokerages

Iqvia Holdings Inc (NYSE:IQV) has been given an average recommendation of “Buy” by the twenty-two research firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, fourteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $131.06.

A number of equities research analysts recently issued reports on IQV shares. Royal Bank of Canada reaffirmed a “$110.25” rating and issued a $128.00 target price on shares of Iqvia in a research note on Thursday, July 19th. ValuEngine upgraded Iqvia from a “hold” rating to a “buy” rating in a report on Thursday, July 12th. SunTrust Banks increased their price target on Iqvia to $140.00 and gave the company a “buy” rating in a report on Wednesday, July 25th. Stifel Nicolaus increased their price target on Iqvia from $128.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 25th. Finally, Bank of America upgraded Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 price target for the company in a report on Wednesday, July 25th.

In other news, insider Kevin C. Knightly sold 9,216 shares of the stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $126.46, for a total transaction of $1,165,455.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director John G. Danhakl sold 221,900 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $126.63, for a total transaction of $28,099,197.00. The disclosure for this sale can be found here. Insiders have sold 601,586 shares of company stock worth $75,510,422 in the last ninety days. Corporate insiders own 6.00% of the company’s stock.

Several hedge funds have recently modified their holdings of IQV. Nomura Asset Management Co. Ltd. increased its stake in Iqvia by 1.9% in the third quarter. Nomura Asset Management Co. Ltd. now owns 25,186 shares of the medical research company’s stock valued at $3,268,000 after purchasing an additional 461 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its holdings in shares of Iqvia by 19.4% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,933 shares of the medical research company’s stock worth $293,000 after buying an additional 476 shares during the last quarter. IFM Investors Pty Ltd boosted its holdings in shares of Iqvia by 5.4% in the 3rd quarter. IFM Investors Pty Ltd now owns 9,290 shares of the medical research company’s stock worth $1,205,000 after buying an additional 478 shares during the last quarter. State Treasurer State of Michigan raised its stake in Iqvia by 1.0% in the 3rd quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock valued at $6,266,000 after acquiring an additional 500 shares during the period. Finally, Gateway Investment Advisers LLC raised its stake in Iqvia by 9.1% in the 3rd quarter. Gateway Investment Advisers LLC now owns 6,770 shares of the medical research company’s stock valued at $878,000 after acquiring an additional 563 shares during the period. 91.36% of the stock is currently owned by institutional investors and hedge funds.

Shares of IQV traded down $1.64 during midday trading on Friday, reaching $124.05. 10,823 shares of the stock were exchanged, compared to its average volume of 1,481,199. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09. Iqvia has a twelve month low of $91.57 and a twelve month high of $135.48. The stock has a market capitalization of $24.76 billion, a P/E ratio of 28.48, a price-to-earnings-growth ratio of 1.76 and a beta of 0.81.

Iqvia (NYSE:IQV) last posted its earnings results on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities research analysts forecast that Iqvia will post 5.13 EPS for the current fiscal year.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Read More: How a Put Option Works

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply